FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials

(MedPage Today) -- The FDA should require clinical trials in perioperative therapy for non-small cell lung cancer (NSCLC) to address the individual contributions of neoadjuvant and adjuvant treatment to outcomes, an advisory committee unanimously...